HEPATITIS C CLINICAL TRIAL- VIROLOGY LABORATORY
$317,210N01FY2000DKNIH
University Of Washington, Seattle WA
Investigators
Linked publications & trials
Paper 24950220Paper 24886378Paper 24497530Paper 23258530Paper 22688849Paper 22571902Paper 22359532Paper 22045670Paper 21946897Paper 21931376Paper 21782771Paper 21760886Paper 21699796Paper 21520194Paper 21480316Paper 21440548Paper 21376050Paper 21374690Paper 21335007Paper 21139575Paper 21136163Paper 21129375Paper 21083592Paper 20564351Paper 20362695Paper 20332289Paper 20211180Paper 20101752Paper 20070284Paper 19889888Paper 19852963Paper 19824074Paper 19766643Paper 19747918Paper 19676128Paper 19656286Paper 19445938Paper 19434718Paper 19291787Paper 19052125Paper 18848939Paper 18619701Paper 18157835Paper 17296533Paper 17196293Paper 17140886Paper 17133499Paper 17101320Paper 16871570Paper 16573786Paper 16518754Paper 16136646Paper 15986415Paper 15847697Paper 15726656Paper 15465617Paper 15057741Paper 14715796
Abstract
The Virology Laboratory (VL) shall serve as the central laboratory for hepatitis C virus testing as well as a central repository for serum and liver tissue from patients participating in the study. The VL shall provide expert advice regarding virological testing and how results can provide further insights into the natural history of hepatitis C and the effects of interferon therapy. The VL shall work actively with the Steering Committee of the Trial to apply new molecular approaches to the study of patients with chronic hepatitis C participating in this Trial. The VL shall thus provide uniform, efficient and high quality virologicial testing and interpretation in support of the Trial.
View original record on NIH RePORTER →